{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:19:17Z","timestamp":1786925957715,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.yebeh.2016.01.006","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T02:03:22Z","timestamp":1454119402000},"page":"50-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience"],"prefix":"10.1016","volume":"56","author":[{"given":"Yash D.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwaljit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin","family":"Devinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev V.","family":"Kothare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2016.01.006_bb0005","first-page":"909","article-title":"Epilepsy in adults and access to care\u2014United States, 2010","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1542\/peds.2010-1371","article-title":"A national profile of childhood epilepsy and seizure disorder","volume":"129","author":"Russ","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0015","first-page":"CD008295","article-title":"Felbamate as an add-on therapy for refractory epilepsy","author":"Shi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0020","article-title":"Epilepsy: a comprehensive textbook","author":"Engel","year":"1997"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0022-3565(24)38215-1","article-title":"Subtype-selective antagonism of N-methyl-d-aspartate receptors by felbamate: insights into the mechanism of action","volume":"289","author":"Kleckner","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 5","key":"10.1016\/j.yebeh.2016.01.006_bb0030","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1528-1157.1999.tb00913.x","article-title":"Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs","volume":"40","author":"White","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0035","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1528-1157.1997.tb00062.x","article-title":"Evaluation of case reports of aplastic anemia among patients treated with felbamate","volume":"38","author":"Kaufman","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0040","article-title":"Suspension of felbatol use urged","author":"Cruzan","year":"1994"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002018-199921030-00006","article-title":"Felbamate in epilepsy therapy: evaluating the risks","volume":"21","author":"Pellock","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0920-1211(96)00070-8","article-title":"Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group","volume":"25","author":"Avanzini","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(01)00290-X","article-title":"The long-term use of felbamate in children with severe refractory epilepsy","volume":"47","author":"Cilio","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0920-1211(98)00098-9","article-title":"Felbamate in refractory partial epilepsy","volume":"34","author":"Canger","year":"1999","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0065","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.pediatrneurol.2010.02.013","article-title":"Efficacy of felbamate in the treatment of intractable pediatric epilepsy","volume":"42","author":"Zupanc","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0070","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.410320313","article-title":"Felbamate monotherapy: controlled trial in patients with partial onset seizures","volume":"32","author":"Sachdeo","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJM199301073280105","article-title":"Efficacy of felbamate in childhood epileptic encephalopathy (Lennox\u2013Gastaut syndrome)","volume":"328","author":"The Felbamate Study Group in Lennox\u2013Gastaut Syndrome","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0080","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1468-1331.2008.02215.x","article-title":"Efficacy and safety of felbamate in children under 4years of age: a retrospective chart review","volume":"15","author":"Grosso","year":"2008","journal-title":"Eur J Neurol"},{"issue":"Suppl. 7","key":"10.1016\/j.yebeh.2016.01.006_bb0085","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1111\/j.1528-1157.1993.tb04590.x","article-title":"Felbamate in the treatment of Lennox\u2013Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial","volume":"34","author":"Dodson","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0022-3476(05)83302-5","article-title":"Efficacy of felbamate in therapy for partial epilepsy in children","volume":"125","author":"Carmant","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2006.06.020","article-title":"Felbamate: consensus of current clinical experience","volume":"71","author":"Pellock","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0100","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/106002809302700913","article-title":"Felbamate","volume":"27","author":"Graves","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1528-1157.1996.tb00518.x","article-title":"Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation","volume":"37","author":"Hooper","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.01.006_bb0110","first-page":"519","article-title":"Antiepileptic drugs in North America","volume":"62","author":"Akiyama","year":"2010","journal-title":"Brain Nerve"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T08:06:20Z","timestamp":1748765180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":22,"alternative-id":["S1525505016000123"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.01.006","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}